William Alleyne
Critical Care Medicine · Rock Hill, SCNPI 1932192093
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $148,635 of the $198,867 with a category attached, or 74.7%. 35 manufacturers reported payments, led by Mylan Specialty L.p. at 55.2% of the total. Reporting peaked in 2023 at $52,990 and has fallen 88.1% since, to $6,317 in 2025. Among critical care medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 698 payments — averaging $284.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$110K
- AstraZeneca$58K
- GSK$19K
- Viatris Specialty LLC$6K
- Genentech USA, Inc.$2K
- Boehringer Ingelheim$667
- plus $4K from 29 others
Across 17 payments — averaging $906.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$7K
- Chiesi USA, Inc.$7K
- Boehringer Ingelheim$1K
What the payments were for
- Consulting fees$15,7458%
- Speaking & faculty fees$148,63575%
- Travel & lodging$21,14011%
- Food & beverage$13,0717%
- Education$1000%
- Other$1750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 198 | $109,858 |
| AstraZeneca | 158 | $57,822 |
| GSK | 94 | $18,573 |
| Viatris Specialty LLC | 5 | $6,317 |
| Genentech USA, Inc. | 21 | $1,763 |
| Boehringer Ingelheim | 37 | $667 |
| Regeneron Healthcare Solutions, Inc. | 21 | $481 |
| Grifols USA, LLC | 22 | $393 |
| Sanofi | 15 | $343 |
| Insmed, Inc. | 17 | $320 |
| Sunovion Pharmaceuticals Inc. | 19 | $295 |
| Mallinckrodt Hospital Products Inc. | 13 | $280 |
| Teva Pharmaceuticals USA, Inc. | 14 | $232 |
| Baxter Healthcare | 1 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $170 |
| Actelion Pharmaceuticals US, Inc. | 9 | $149 |
| Inspire Medical Systems, Inc. | 1 | $139 |
| Genentech, Inc. | 1 | $120 |
| Pulmonx Corporation | 1 | $105 |
| Novartis | 6 | $96 |
| Philips North America LLC | 4 | $78 |
| Covis Pharma GmbH | 4 | $74 |
| Advanced Respiratory, Inc | 5 | $59 |
| Paratek Pharmaceuticals, Inc. | 3 | $57 |
| Circassia Inc. | 3 | $44 |
| Astellas Pharma US Inc | 3 | $40 |
| Amgen | 2 | $39 |
| CSL Behring | 2 | $39 |
| Optinose US, Inc. | 3 | $37 |
| Merck | 2 | $29 |
| Johnson & Johnson | 1 | $17 |
| Inogen, Inc. | 2 | $16 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$113,857
- FASENRA$31,565
- BREZTRI$18,135
- TRELEGY ELLIPTA$17,383
- BREZTRI AEROSPHERE$1,575
- XOLAIR$1,575
- Inspire$139
- Esbriet$120
- Xofluza$120
- Pulmonx Endobronchial Valve EBV$105
How this compares
$198,867 in reported general payments places this provider in the 95th percentile of 93 critical care medicine providers in South Carolina.
See all critical care medicine providers in South Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $23,176 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $15,250 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $12,780 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $4,924 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $1,356 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,268 |
| Montelukast Sodium | 26 | $482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $18,573 | $43,35066 claims |
| AstraZenecaBreztri Aerosphere | $57,822 | $12,78015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 93 critical care medicine providers in South Carolina.
Other critical care medicine in Rock Hill
- Charlton StrangeCharleston$205K
- Rahul ArgulaCharleston$186K
- James CarswellCharleston$159K
- Daniel HerrHilton Head Island$151K
- Hafez HayekConway$138K
- Nicholas FoxCharleston$88K
- Nasir AwanGreenville$54K
- Christopher GilbertCharleston$44K
- Ikenna OnyebuekeSpartanburg$34K
- Rico Vicente MendozaSpartanburg$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.